韩国2008-2018年耐氟康唑光滑念珠菌血流分离株研究
该研究调查了韩国多中心2008-2018年收集的1,158株光滑念珠菌血流分离株中耐氟康唑株的临床结局与分子机制,发现5.7%为耐氟康唑株。64例耐氟康唑血流感染患者30天死亡率为60.9%、90天死亡率为78.2%,显著高于氟康唑剂量依赖性敏感株患者(30天36.4%、90天43.8%,p<0.05)。适当抗真菌治疗是耐氟康唑株患者30天和90天死亡率的唯一独立保护因素。
要点
- 耐氟康唑光滑念珠菌血流感染患者30天死亡率60.9%、90天死亡率78.2%,显著高于敏感株患者。
- 适当抗真菌治疗是耐氟康唑株患者30天和90天死亡率的唯一独立保护因素。
- 98.5%的耐氟康唑株携带Pdr1p额外氨基酸替换,而敏感株仅0.9%。
核心结论
- 耐氟康唑光滑念珠菌血流感染患者死亡率高,且多数分离株携带Pdr1p突变。
- 适当抗真菌治疗与耐氟康唑株患者30天和90天死亡率降低独立相关。
研究设计与样本
- 基于韩国多中心研究2008-2018年收集的1,158株光滑念珠菌血流分离株。
- 对64例耐氟康唑血流感染患者分析临床结局与分子机制。
主要发现
- 1,158株分离株中5.7%为耐氟康唑。
- 耐氟康唑株患者30天死亡率60.9%、90天死亡率78.2%,显著高于氟康唑剂量依赖性敏感株患者的30天36.4%、90天43.8%(p<0.05)。
- 适当抗真菌治疗是耐氟康唑株患者30天(风险比0.304)和90天(风险比0.310)死亡率的唯一独立保护因素。
- 98.5%的耐氟康唑株存在1-2个额外Pdr1p氨基酸替换(除外基因型特异性替换),而氟康唑剂量依赖性敏感株仅0.9%。
关键数值与推荐
- 耐氟康唑株30天死亡率60.9%,90天死亡率78.2%。
- 氟康唑剂量依赖性敏感株30天死亡率36.4%,90天死亡率43.8%(p<0.05)。
- 适当抗真菌治疗30天死亡率风险比0.304,90天风险比0.310。
- 耐氟康唑株中98.5%携带额外Pdr1p氨基酸替换,敏感株中0.9%。
临床怎么用
- 对光滑念珠菌血流感染应关注氟康唑耐药风险,及时进行药敏检测。
- 耐氟康唑光滑念珠菌血流感染患者应尽早给予适当抗真菌治疗以改善预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We investigated the clinical outcomes and molecular mechanisms of fluconazole-resistant (FR) Candida glabrata bloodstream infections. Among 1,158 isolates collected during multicenter studies in South Korea during 2008–2018, 5.7% were FR. For 64 patients with FR bloodstream infection isolates, the 30-day mortality rate was 60.9% and the 90-day mortality rate 78.2%; these rates were significantly higher than in patients with fluconazole-susceptible dose-dependent isolates (30-day mortality rate 36.4%, 90-day mortality rate 43.8%; p<0.05). For patients with FR isolates, appropriate antifungal therapy was the only independent protective factor associated with 30-day (hazard ratio 0.304) and 90-day (hazard ratio 0.310) mortality. Sequencing of pleiotropic drug-resistance transcription factor revealed that 1–2 additional Pdr1p amino acid substitutions (except genotype-specific Pdr1p amino acid substitutions) occurred in 98.5% of FR isolates but in only 0.9% of fluconazole-susceptible dose-dependent isolates. These results highlight the high mortality rate of patients infected with FR C. glabrata BSI isolates harboring Pdr1p mutations. Nearly all isolates harbored Pdr1p mutations and were associated with a high mortality rate.
引用
- Won EJ, Choi MJ, Kim MN, et al. Fluconazole-Resistant Candida glabrata Bloodstream Isolates, South Korea, 2008-2018. Emerg Infect Dis. 2021. PMID: 33624581. doi:10.3201/eid2703.203482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。